Halozyme Reports First Quarter 2021 Results
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/23/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- China, US, UAE police arrest 276 telecom fraud suspects in Dubai
- Qtrex Quantum executives plan to buy up to 2M shares over 12 months
Halozyme Therapeutics (HALO) Tops Q1 EPS by 5c, Revenues Beat; Offers FY21 EPS Mid-Point Guidance Above Consensus, FY21 Revs. Mid-Point Views Below Consensus
May 10, 2021 4:57 PM EDTHalozyme Therapeutics (NASDAQ: HALO) reported Q1 EPS of $0.37, $0.05 better than the analyst estimate of $0.32. Revenue for the quarter came in at $89 million versus the consensus estimate of $84.88 million.
"The first quarter marked a strong start to 2021 highlighted by record quarterly royalty revenue driven by the continued successful launch of subcutaneous DARZALEX® worldwide," said Dr. Helen Torley, president and chief executive officer. "Our pipeline of partnered product candidates using ENHANZE®... More
